Evaluation of the safety of <scp>PD</scp>‐1/<scp>PD</scp>‐<scp>L1</scp> inhibitors for immunotherapy in patients with malignant tumors after <scp>COVID</scp>‐19 infection: A single‐center cohort study
Our findings suggest that infection with COVID-19 does not significantly impact the safety of PD-1/PD-L1 inhibitors in cancer patients. Most cancer patients used PD-1/PD-L1 inhibitors during COVID-19 infection (asymptomatic or mild infection) did not experience exacerbation of their underlying condition, nor did they exhibit a substantial increase in toxic side effects.
Authors
- Beining Zhang (ORCID: https://orcid.org/0009-0000-6235-0952)
- Long Huang (ORCID: https://orcid.org/0000-0002-5372-071X)
- Xinyi Bai (ORCID: https://orcid.org/0009-0002-7594-4404)
- Wenyige Zhang
- Huan Hu (ORCID: https://orcid.org/0000-0002-9749-0741)
- Jinting Cheng
- Peng Huang (ORCID: https://orcid.org/0009-0001-0812-4310)
- Kaili Liao
- Yujie Hu (ORCID: https://orcid.org/0009-0002-7034-9139)
- Yuchen Zhu
- Y. Xu
- Yihui Qian
- Kun Ai
- Jie Liu (ORCID: https://orcid.org/0009-0006-5054-4550)
Institutions
- Nanchang University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/cam4.70202
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- National Natural Science Foundation of China